Search Results

“Stages” of Leukemia: Understanding Classification and Progression

Table of contents

Ofatumumab

Ofatumumab is FDA approved

For the treatment of patients who have chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.
In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL), for whom fludarabine-based therapy is considered inappropriate.

NCI-Genetic Epidemiology Branch - Familial CLL

To study families with multiple cases of chronic lymphocytic leukemia (CLL).

The National Cancer Institute (NCI) of the National Institutes of Health (NIH) is conducting a study to: find the gene or genes that cause this type of leukemia to occur in families; to describe the clinical features of familial CLL; to explore whether families prone to familial CLL are also at greater risk of other types of leukemia or cancer; to identify biomarkers or markers that predict risk in family members.
Participants will be asked to provide a blood sample or cells, personal and medical history, and to give consent to obtain medical records.

Families with 2 or more living individuals in the family with a history of CLL, or families in which one family member has CLL and one or more close relatives have a related blood or lymph cancer

800-518-8474 http://dceg.cancer.gov/research/clinical-studies/blood-cll-info

Spotlight on Caregiving: Chronic Lymphocytic Leukemia (CLL)

Evolutionary Behavior in CLL: Implications for Personalized Therapy

Fact or Fiction? CLL Treatment and Side Effects

Advances in Treatment for Chronic Lymphocytic Leukemia (CLL)

Rituximab and hyaluronidase human

Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:

Panelists Discuss the AML Patient Experience

What is AML? What research is underway? And what resources are available to patients?

The Leukemia & Lymphoma Society recently joined up with Patient Power and the MDS Alliance to host an AML Awareness Day and answer those questions.

The April 21 webcast was moderated by Carol Preston, host of Patient Power, an online portal offering cancer information for both patients and professionals. Preston is also a chronic lymphocytic leukemia (CLL) survivor.

A phase 1 study of CB-012, a CRISPR-edited allogeneic CAR-T targeting CLL1, in patients with acute myeloid leukemia

In February 2021, LLS made an equity investment in Caribou Biosciences to "Support allogeneic CD371 (CLL-1) CAR development for acute myeloid leukemia." Caribou is a clinical-stage biotechnology company, co-founded by CRISPR pioneer and Nobel Prize winner Jennifer Doudna, Ph.D., using next-generation CRISPR genome-editing technology to develop “off-the-shelf” (allogeneic) CAR therapies for hard-to-treat blood cancers.

A researcher analyzes a specimen in a test tube.

Blood Cancer Research Poised for Another ‘Banner Year’ in 2024

More than 25,000 medical professionals from across the world came together in December to discuss the latest blood cancer developments during the annual meeting of the American Society of Hematology (ASH). This annual event gives us the opportunity to think about what advances are on the horizon as LLS works to strengthen cures, care and quality of life for people with blood cancer and their families.

Is Leukemia Genetic?

Table of contents

Advances in Blood Cancers: Making NHL & CLL Treatment Decisions

Chronic Lymphocytic Leukemia (CLL): What Are My Treatment Options?

Predisposing factors to leukemia

Table of contents:

#ASH18: The Beat Goes On

On Sunday, I reported on a press briefing at the 60th ASH Annual Meeting where the preliminary findings of our Beat AML Master Clinical Trial were unveiled. This innovative collaborative study is designed to bring the hope of precision medicine to patients with acute myeloid leukemia (AML). (Read about our Friday ASH satellite symposium on immunotherapy here).

Rituximab

is FDA approved for the treatment of:

Idelalisib

Idelalisib is FDA approved to treat patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.

Venetoclax

Venetoclax is FDA approved

For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Researcher wearing a hair net, N95 mask and gloves injects a liquid into a vial.

The Leukemia & Lymphoma Society's New Chief Scientific Officer Excited about What's Next in Blood Cancer Research

Lore Gruenbaum, Ph.D., was promoted to The Leukemia & Lymphoma Society’s (LLS) Chief Scientific Officer (CSO) following the retirement of longtime CSO Lee Greenberger, Ph.D. on December 31. We talked with Dr. Gruenbaum about her new role and what’s on the horizon for blood cancer research in 2025.

“It’s a privilege to lead a group of dedicated LLS scientists to seek out and fund innovative science for every type of blood cancer,” says Dr. Gruenbaum.

Chlorambucil

Chlorambucil is FDA approved to treat people who have chronic lymphocytic leukemia (CLL), some types of non-Hodgkin lymphoma and advanced Hodgkin lymphoma.

Bendamustine hydrochloride

Bendamustine hydrochloride is FDA approved to treat people who have:

Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Acalabrutinib

Acalabrutinib is a kinase inhibitor indicated:

In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT).
For the treatment of adult patients with MCL who have received at least one prior therapy.
For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Alemtuzumab

Alemtuzumab is FDA approved to treat people who have chronic lymphocytic leukemia (CLL).